Nine Tumors After Zolgensma: What the Structure of Molecules Can Teach Us (and What It Can't)
Nine tumors after Zolgensma: what the structure of molecules can teach us (and what it can't) Novartis has confirmed nine cases of tumors in children treated with Zolgensma, according to a press release reported by GEN — Genetic Engineering and Biotechnology News. Two cases to date show evidence of vector integration into the patients' DNA. In both cases, the patients…
Novartis has confirmed nine cases of tumors in children treated with Zolgensma, according to a report by GEN — Genetic Engineering and Biotechnology News. Two of these cases show evidence of the vector integrating into the patients' DNA, and the patients are being treated and monitored. The incidents highlight the complexity of gene therapy and the need for rigorous pharmacovigilance.
The integration of the vector into the host genome is a problem that occurs on multiple scales, including sequence, chromatin, and structure. The structural scale remains the most difficult to inspect and communicate, and new tools, such as immersive visualization, may provide a new perspective on molecular interactions.
Written by urgent.news from Dev.to's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
